Updates are available Correction dated 2024-06-26
Click to view Correction: https://doi.org/10.1038/s41408-024-01058-y
-
Authors
Hu, Mengshi
Yang, Tao
Yang, Linyu
Niu, Lu
Zhu, Jinbing
Zhao, Ailin
Shi, Mingsong
Yuan, Xue
Tang, Minghai
Yang, Jianhong
Pei, Heying
Yang, Zhuang
Chen, Qiang https://orcid.org/0000-0002-2398-4482
Ye, Haoyu
Niu, Ting https://orcid.org/0000-0003-1580-1014
Chen, Lijuan https://orcid.org/0000-0002-8076-163X
-
Funding
Funding for this research was provided by:
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosi
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosis
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosis
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosis
Research of the 1.1-type new drug "Flonoltinib" for the treatment of myelofibrosis
- License Information
-
More Information
Article History
Received: 22 August 2021
Revised: 24 January 2022
Accepted: 26 January 2022
First Online: 7 March 2022
Change Date: 26 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-024-01058-y
Competing interests
: The authors declare no competing interests.
